261 related articles for article (PubMed ID: 29435776)
1. Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial.
Ueda S; Shimabukuro M; Arasaki O; Node K; Nomiyama T; Morimoto T
Cardiovasc Drugs Ther; 2018 Feb; 32(1):73-80. PubMed ID: 29435776
[TBL] [Abstract][Full Text] [Related]
2. Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.
Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
Cardiovasc Diabetol; 2020 Jun; 19(1):89. PubMed ID: 32539832
[TBL] [Abstract][Full Text] [Related]
3. Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial.
Chihara A; Tanaka A; Morimoto T; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Ueda S; Node K
Cardiovasc Diabetol; 2019 Nov; 18(1):158. PubMed ID: 31733647
[TBL] [Abstract][Full Text] [Related]
4. Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.
Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
J Atheroscler Thromb; 2022 Jan; 29(1):24-37. PubMed ID: 33342939
[TBL] [Abstract][Full Text] [Related]
5. Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial.
Morimoto T; Sakuma I; Sakuma M; Tokushige A; Natsuaki M; Asahi T; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
Sci Rep; 2019 Jun; 9(1):8537. PubMed ID: 31189978
[TBL] [Abstract][Full Text] [Related]
6. Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients.
Tahara N; Yamagishi SI; Bekki M; Kodama N; Nakamura T; Sugiyama Y; Oshige T; Kumashiro Y; Honda A; Tahara A; Igata S; Fukumoto Y
Curr Vasc Pharmacol; 2016; 14(6):552-562. PubMed ID: 27357182
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial.
Onoue T; Goto M; Wada E; Furukawa M; Okuji T; Okada N; Kobayashi T; Iwama S; Sugiyama M; Tsunekawa T; Takagi H; Hagiwara D; Ito Y; Morishita Y; Seino Y; Suga H; Banno R; Hamada Y; Ando M; Yamamori E; Arima H
PLoS One; 2020; 15(1):e0228004. PubMed ID: 31990936
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
[TBL] [Abstract][Full Text] [Related]
9. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study.
Shigiyama F; Kumashiro N; Fuchigami A; Hirose T
Cardiovasc Diabetol; 2018 Jun; 17(1):86. PubMed ID: 29895330
[TBL] [Abstract][Full Text] [Related]
11. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
Hiruma S; Shigiyama F; Hisatake S; Mizumura S; Shiraga N; Hori M; Ikeda T; Hirose T; Kumashiro N
Cardiovasc Diabetol; 2021 Feb; 20(1):32. PubMed ID: 33530982
[TBL] [Abstract][Full Text] [Related]
12. Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study.
Tomiyama H; Miwa T; Kan K; Matsuhisa M; Kamiya H; Nanasato M; Kitano T; Sano H; Ohno J; Iida M; Sata M; Yamada H; Maemura K; Tanaka A; Murohara T; Node K
Cardiovasc Diabetol; 2016 Nov; 15(1):150. PubMed ID: 27809848
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.
Ayaori M; Iwakami N; Uto-Kondo H; Sato H; Sasaki M; Komatsu T; Iizuka M; Takiguchi S; Yakushiji E; Nakaya K; Yogo M; Ogura M; Takase B; Murakami T; Ikewaki K
J Am Heart Assoc; 2013 Jan; 2(1):e003277. PubMed ID: 23525426
[TBL] [Abstract][Full Text] [Related]
14. Anagliptin twice-daily regimen improves glycaemic variability in subjects with type 2 diabetes: A double-blind, randomized controlled trial.
Lee YH; Kim DM; Yu JM; Choi KM; Kim SG; Park KS; Son HS; Chung CH; Ahn KJ; Lee SH; Song KH; Kwon SK; Park HK; Won KC; Jang HC;
Diabetes Obes Metab; 2023 May; 25(5):1174-1185. PubMed ID: 36564983
[TBL] [Abstract][Full Text] [Related]
15. A Multi-Center, Open-Label, Two-Arm Parallel Group Non-inferiority Randomized Controlled Trial Evaluating the Effect of Pitavastatin, Compared to Atorvastatin, on Glucose Metabolism in Prediabetics with Hypertension and Dyslipidemia: Rationale and Design for the China Hemoglobin A1c Metabolism Protection Union Study (CAMPUS).
Zhang J; Shao Y; Liu Y; Tao J
Cardiovasc Drugs Ther; 2018 Dec; 32(6):581-589. PubMed ID: 30187345
[TBL] [Abstract][Full Text] [Related]
16. Effect of Canagliflozin Compared With Sitagliptin on Serum Lipids in Patients with Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: A Post-Hoc Analysis of the CANA-HF Study.
Dixon DL; Billingsley HE; Canada JM; Trankle CR; Kadariya D; Cooke R; Hart L; Van Tassell B; Abbate A; Carbone S
J Cardiovasc Pharmacol; 2021 Sep; 78(3):407-410. PubMed ID: 34132690
[TBL] [Abstract][Full Text] [Related]
17. Anagliptin decreases serum lathosterol level in patients with type 2 diabetes: a pilot study.
Aoki K; Ijima T; Kamiyama H; Kamiko K; Terauchi Y
Expert Opin Pharmacother; 2015; 16(12):1749-54. PubMed ID: 26098722
[TBL] [Abstract][Full Text] [Related]
18. Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy.
Widlansky ME; Puppala VK; Suboc TM; Malik M; Branum A; Signorelli K; Wang J; Ying R; Tanner MJ; Tyagi S
Vasc Med; 2017 Jun; 22(3):189-196. PubMed ID: 28145158
[TBL] [Abstract][Full Text] [Related]
19. Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial.
Hirai H; Higa M; Morimoto T; Sakuma M; Arasaki O; Nomiyama T; Node K; Ueda S; Shimabukuro M
J Clin Med; 2019 Dec; 9(1):. PubMed ID: 31905896
[TBL] [Abstract][Full Text] [Related]
20. Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension.
Jin SM; Park SW; Yoon KH; Min KW; Song KH; Park KS; Park JY; Park IB; Chung CH; Baik SH; Choi SH; Lee HW; Lee IK; Kim DM; Lee MK
Diabetes Obes Metab; 2015 May; 17(5):511-5. PubMed ID: 25523633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
